- About Us
- Services & Solutions
- Novel Technology Platform
- Bioconjugation Discovery
- Bioconjugation Process Development
- Analytical Development
- Formulation and DP Development
- GMP mAb Intermediate and Conjugation Manufacturing
- GMP Formulation, Fill and Lyophilization
- Payload and Linker R&D and Manufacturing
- Ready-Made Payloads & Linkers
- WuXi XDC Singapore Site
- Investor Relations
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- Investor RelationsAbout Us
- News & ResourcesAbout Us
Scientific Poster Download
Poster modified on 29/01/2026
Formulation Challenges and WuXi XDC Capabilities: from ADC to XDC
Weipeng Mao, Tianyu Xia, Lili Wen, Jin Sun, Jiayi You, Boyang Si, Xiaobo Xi, Chunyuan Jia, J.J. Luo
WuXi XDC, Co. Ltd.
WuXi XDC bioconjugate product development team leverages innovative platform capabilities to tackle the formulation challenges of novel ADC and XDC. The strength of our formulation platform lies in its ability to help biopharma companies dramatically reduce formulation development risks, allowing them to focus on selecting best fitted candidates and commercialization strategy. As a dedicated CRDMO, we provide innovative technology platforms and solutions to address formulation challenges lead by ADC to XDC.
- High-throughput formulation screening
- High dose formulation development
- Photosensitive formulation development
Discuss This Poster
To discuss the data in this poster, please complete the form on the following page to connect with our experts.
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?